

Recombinant Human Interleukin-2 (IL-2)

Catalog Number PHC0026 (10 µg), PHC0027 (40 µg), PHC0021 (100 µg), PHC0023 (1 mg)

Pub. No. MAN0004191 Rev. A.0

Product specifications

Lot number	See product label.
Molecular weight	15.5 kDa
Purity	>95% as determined by SDS PAGE analysis.
Biological activity	ED ₅₀ <0.500 ng/mL, determined by the dose dependent proliferation of mouse CTLL-2 cells. Determine the optimal concentration for each specific application using an initial dose response assay.
Formulation	Lyophilized, carrier-free.
Sterility	Filtered before lyophilization through a 0.22 micron sterile filter.
Endotoxin	<0.1 ng/µg
Production	Produced in <i>E. coli</i> and purified via gel filtration chromatography.
Reconstitution recommendation	Centrifuge the vial briefly, before opening to bring the contents to the bottom. Reconstitute the lyophilized protein in 100 mM acetic acid to 0.1–1.0 mg/mL to regain full activity. Apportion the reconstituted protein into working aliquots and store at ≤ –20°C. Make any further dilutions of the reconstituted protein in low endotoxin medium or buffered solution with FBS or tissue culture grade BSA.
Suggested working dilutions	The optimal concentration should be determined for each specific application.
Storage	Store the lyophilized protein at 2–8°C, preferably desiccated. Upon reconstitution, apportion into working aliquots and store at ≤ –20°C (not in a frost-free freezer). Avoid repeated freeze-thaw cycles.
Expiration date	Expires one year from date of receipt when stored as instructed.
References	<p>Blumenthal, RL, Campbell, DE, Hwang, P, DeKruyff, RH, Frankel, LR, and Umetsu, DT. (2001) Human alveolar macrophages induce functional inactivation in antigen-specific CD4 T cells. <i>J. Allergy Clin. Immunol.</i> 107(2):258–264.</p> <p>Camporeale, G. and Zempleni, J. (2003) Oxidative folding of interleukin-2 is impaired in flavin-deficient Jurkat cells, causing intracellular accumulation of interleukin-2 and increased expression of stress response genes. <i>Journal of Nutrition</i> 133(3):668–672.</p> <p>Chen, M, Gran, B, Costello, K, Johnson, K, Martin, R, and Dhib-Jalbut, S. (2001) Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. <i>Multiple Sclerosis</i> 7(4):209–219.</p> <p>Cochran, JR, Cameron, TO, Stone, JD, Lubetsky, JB, and Stern, LJ. (2001) Receptor proximity, not intermolecular orientation is critical for triggering T-cell activation. <i>J. Biol. Chem.</i> 276(30):28068–28074.</p> <p>Esser, MT, Haverstick, DM, Fuller, CL, Gullo, CA, and Braciale, VL. (1998) Ca²⁺ signaling modulates cytolytic T lymphocyte effector functions. <i>J. Exp. Med.</i> 187(7):1057–1067.</p> <p>Fan, R, Tykodi, SS, and Braciale, TJ. (2000) Recognition of a sequestered self peptide by influenza virus-specific CD8(+) cytolytic T lymphocytes. <i>J. Immunol.</i> 164:1669–1680.</p> <p>Graham, MB, and Braciale, TJ. (1997) Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. <i>J. Exp. Med.</i> 186(12):2063–2068.</p> <p>Guilherme, L, Oshiro, SE, Fae, KC, Cunha-Neto, E, Renesto, G, Goldberg, AC, Tanaka, AC, Pomerantzeff, PMA, Kiss, MH, Silva, C, Guzman, F, Patarroyo, ME, Southwood, S, Sette, A and Kalil, J. (2001) T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. <i>Infection Immunity</i> 69(9):5345–5351.</p> <p>Gullo, CA, Esser, MT, Fuller, CL, and Braciale, VL. (1999) Generation of IL-2-dependent cytolytic T lymphocytes (CTLs) with altered TCR responses derived from antigen-dependent CTL clones. <i>J. Immunol.</i> 162 (11):6466– 6472.</p> <p>Kemper, C, Chan, AC, Green, JM, Brett, KA, Murphy, KM, and Atkinson, JP. (2003) Activation of human CD4(+) cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. <i>Nature</i> 421(6921):388–392.</p>

References , continued	<p>Kindt, TJ, Said, WA, Bowers, FS, Mahana, W, Zhao, TM, and Simpson, RM. (2000) Passage of human T-cell leukemia virus type-1 during progression to cutaneous T-cell lymphoma results in myelopathic disease in an HTLV-1 infection model. <i>Microbes and Infection</i> 2(10):1139–1146.</p> <p>Loparev, V, Parsons, J, Knight, J, Fanelli Panus, J, Ray, C, Buller, R, Pickup, D, and Esposito, J. (1998) A third distinct tumor necrosis factor receptor of orthopoxviruses. <i>Proc. Nat'l. Acad. Sci.</i> 95(7):3786–3791.</p> <p>Molldrem, JJ, Lee, PP, Kant, S, Wieder, E, Jiang, WD, Lu, SJ, Wang, CQ, and Davis, MM. (2003) Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. <i>J. Clin. Invest.</i> 111(5):639–647.</p> <p>Rajan, R, Vanderslice, R, Kapur, S, Lynch, J, Thompson, R, and Djakiew, D. (1996) Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. <i>Prostate</i> 28(1):1–9.</p> <p>Robey, FA, and Robert-Guroff, M. (2001) A defined conformational epitope from the C4 domain of HIV type 1 glycoprotein 120: Anti-cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells. <i>Aids Research and Human Retroviruses</i> 17(6):533–541.</p> <p>Stranick, KS, Zambas, DN, Uss, AS, Egan, RW, Billah, MM, and Umland, SP. (1997) Identification of transcription factor binding sites important in the regulation of the human interleukin-5 gene. <i>J. Biol. Chem.</i> 272(26):16453–16465.</p> <p>Wagers, AJ, Waters, CM, Stoolman, LM, and Kansas, GS. (1998) Interleukin 12 and interleukin 4 control T cell adhesion to endothelial selectins through opposite effects on alpha1, 3-fucosyltransferase VII gene expression. <i>J. Exp. Med.</i> 188(12):2225–2231.</p> <p>Weng, Y, Siciliano, SJ, Waldburger, KE, Sirotina-Meisher, A, Staruch, MJ, Daugherty, BL, Gould, SL, Springer, MS, and DeMartino, JA. (1998) Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. <i>J. Biol. Chem.</i> 273(29):18288–18291.</p>
-------------------------------	---

Limited product warranty

Life Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies' General Terms and Conditions of Sale at www.thermofisher.com/us/en/home/global/terms-and-conditions.html. If you have any questions, please contact Life Technologies at www.thermofisher.com/support.

Explanation of Symbols

Symbol	Description	Symbol	Description	Symbol	Description
	Manufacturer		Catalog number		Batch code
	Use by		Temperature limitation		
	Consult instructions for use		Caution, consult accompanying documents		

Life Technologies Corporation | 5781 Van Allen Way | Carlsbad, CA 92008
For descriptions of symbols on product labels or product documents, go to thermofisher.com/symbols-definition.

The information in this guide is subject to change without notice.

DISCLAIMER: TO THE EXTENT ALLOWED BY LAW, THERMO FISHER SCIENTIFIC INC. AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT.

Important Licensing Information: This product may be covered by one or more Limited Use Label Licenses. By use of this product, you accept the terms and conditions of all applicable Limited Use Label Licenses.

©2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.